The U.S. Centers for Medicare & Medicaid Services granted reimbursement for Illumina’s TruSight Oncology Comprehensive assay at $2,989.55 per test, effective Jan. 1, 2026, under PLA code 0543U. The FDA‑approved comprehensive genomic profiling test interrogates more than 500 genes and is cleared as a companion diagnostic for select targeted therapies. CMS coverage removes a key adoption barrier for comprehensive genomic profiling in solid tumors and could accelerate usage of CGP in community and academic settings. Illumina said the decision will expand access to precision oncology insights that guide treatment selection and support enrollment in biomarker‑driven trials.